Literature DB >> 25633969

Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.

Jianjun Cheng1, Patrick M Giguère, Oluseye K Onajole, Wei Lv, Arsen Gaisin, Hendra Gunosewoyo, Claire M Schmerberg, Vladimir M Pogorelov, Ramona M Rodriguiz, Giulio Vistoli, William C Wetsel, Bryan L Roth, Alan P Kozikowski.   

Abstract

The discovery of a new series of compounds that are potent, selective 5-HT2C receptor agonists is described herein as we continue our efforts to optimize the 2-phenylcyclopropylmethylamine scaffold. Modifications focused on the alkoxyl substituent present on the aromatic ring led to the identification of improved ligands with better potency at the 5-HT2C receptor and excellent selectivity against the 5-HT2A and 5-HT2B receptors. ADMET studies coupled with a behavioral test using the amphetamine-induced hyperactivity model identified four compounds possessing drug-like profiles and having antipsychotic properties. Compound (+)-16b, which displayed an EC50 of 4.2 nM at 5-HT2C, no activity at 5-HT2B, and an 89-fold selectivity against 5-HT2A, is one of the most potent and selective 5-HT2C agonists reported to date. The likely binding mode of this series of compounds to the 5-HT2C receptor was also investigated in a modeling study, using optimized models incorporating the structures of β2-adrenergic receptor and 5-HT2B receptor.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633969      PMCID: PMC4834193          DOI: 10.1021/jm5019274

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

1.  HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.

Authors:  Alan P Kozikowski; Sung Jin Cho; Niels H Jensen; John A Allen; Andreas M Svennebring; Bryan L Roth
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

Review 2.  5-HT2 receptors.

Authors:  J E Leysen
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2004-02

Review 3.  5-HT2C receptor modulators: a patent survey.

Authors:  Junwon Lee; Myung Eun Jung; Jinhwa Lee
Journal:  Expert Opin Ther Pat       Date:  2010-09-17       Impact factor: 6.674

4.  Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.

Authors:  Gang Chen; Sung Jin Cho; Xi-Ping Huang; Niels H Jensen; Andreas Svennebring; Maria F Sassano; Bryan L Roth; Alan P Kozikowski
Journal:  ACS Med Chem Lett       Date:  2011-10-10       Impact factor: 4.345

5.  Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors.

Authors:  Cedric Mombereau; Yukio Kawahara; Brigitta B Gundersen; Kazuko Nishikura; Julie A Blendy
Journal:  Neuropharmacology       Date:  2010-07-17       Impact factor: 5.250

6.  5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.

Authors:  D Fiorella; S Helsley; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

Review 7.  Targeting 5-HT receptors for the treatment of obesity.

Authors:  Bruce J Sargent; Alan J Henderson
Journal:  Curr Opin Pharmacol       Date:  2011-02-15       Impact factor: 5.547

8.  Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP).

Authors:  P M Callahan; K A Cunningham
Journal:  Eur J Pharmacol       Date:  1994-05-12       Impact factor: 4.432

9.  Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

Authors:  M J Millan; A Dekeyne; A Gobert
Journal:  Neuropharmacology       Date:  1998-07       Impact factor: 5.250

10.  Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.

Authors:  J Liu; A Ogden; T A Comery; A Spiros; P Roberts; H Geerts
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-04-23
View more
  8 in total

1.  Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis.

Authors:  Yuan-Qiang Wang; Wei-Wei Lin; Nan Wu; Si-Yi Wang; Mao-Zi Chen; Zhi-Hua Lin; Xiang-Qun Xie; Zhi-Wei Feng
Journal:  Acta Pharmacol Sin       Date:  2019-02-27       Impact factor: 6.150

2.  Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism.

Authors:  Guiping Zhang; John D McCorvy; Sida Shen; Jianjun Cheng; Bryan L Roth; Alan P Kozikowski
Journal:  Eur J Med Chem       Date:  2019-08-14       Impact factor: 6.514

3.  5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.

Authors:  Vladimir M Pogorelov; Ramona M Rodriguiz; Jianjun Cheng; Mei Huang; Claire M Schmerberg; Herbert Y Meltzer; Bryan L Roth; Alan P Kozikowski; William C Wetsel
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

4.  Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.

Authors:  Jianjun Cheng; Patrick M Giguere; Claire M Schmerberg; Vladimir M Pogorelov; Ramona M Rodriguiz; Xi-Ping Huang; Hu Zhu; John D McCorvy; William C Wetsel; Bryan L Roth; Alan P Kozikowski
Journal:  J Med Chem       Date:  2016-01-13       Impact factor: 7.446

5.  We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.

Authors:  Jianjun Cheng; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2015-10-28       Impact factor: 3.466

6.  Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51.

Authors:  Wei Lv; Brian Budke; Michal Pawlowski; Philip P Connell; Alan P Kozikowski
Journal:  J Med Chem       Date:  2016-04-21       Impact factor: 7.446

Review 7.  The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.

Authors:  Attila Egyed; Dóra Judit Kiss; György M Keserű
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

8.  Synthesis and Biological Evaluation of Disubstituted Pyrimidines as Selective 5-HT2C Agonists.

Authors:  Juhyeon Kim; Yoon Jung Kim; Ashwini M Londhe; Ae Nim Pae; Hyunah Choo; Hak Joong Kim; Sun-Joon Min
Journal:  Molecules       Date:  2019-09-05       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.